Impact of cranial stereotactic radiotherapy associated with immunotherapy with nivolumab and ipilimumab on overall survival in patients with melanoma brain metastases: a real-world evidence
- PMID: 35546648
- DOI: 10.1007/s12094-022-02838-3
Impact of cranial stereotactic radiotherapy associated with immunotherapy with nivolumab and ipilimumab on overall survival in patients with melanoma brain metastases: a real-world evidence
Abstract
Purpose: To evaluate the impact of cranial stereotactic radiotherapy (SRT) on overall survival (OS) of melanoma brain metastases (MBM) patients treated with combined nivolumab and ipilimumab (CNI) in a contemporary and real-world setting.
Methods/patients: The study was performed by using TriNetX, a global health network dataset of electronic medical records from patients in 49 healthcare organizations. We queried for patients with specific terms between January 2016 and December 2020 and run a propensity score matching (PSM) analysis. OS was estimated by Kaplan-Meier and log-rank test was applied.
Results: After initial query and PSM, 114 patients were selected in each cohort. Median OS was 327 days in CNI and not reached in the CNI + SRT cohort, with OS probability of 54.4 and 40.9%, respectively (log-rank P = .0057). CNI + SRT was associated with significantly decreased mortality (HR, 0.57; 95% CI 0.377-0.853; proportionality P = .0034).
Conclusions: This real-world analysis showed that CNI + SRT led to an improvement in OS compared to CNI.
Keywords: Brain metastases; Immunotherapy; Melanoma; Radiosurgery.
© 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
References
-
- Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722–30. https://doi.org/10.1056/NEJMoa1805453 . - DOI - PubMed - PMC
-
- Sperduto PW, Mesko S, Li J, et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol. 2020;38(32):3733–84. https://doi.org/10.1200/JCO.20.01255 . - DOI
-
- Shinde A, Li R, Amini A, Glaser S. Can immunotherapy replace radiotherapy in melanoma brain metastases? J Clin Oncol. 2019;37(12):1030–1. https://doi.org/10.1200/JCO.18.01982 . - DOI - PubMed
-
- Hong AM, Fogarty GB, Dolven-Jacobsen K, et al. Adjuvant whole-brain radiation threrapy compared with observation after local treatment of melanoma brain metastases: a multicenter, randomized phase iii trial. J Clin Oncol. 2019;37(33):3132–41. https://doi.org/10.1200/JCO.19.01414 . - DOI - PubMed
-
- Amaral T, Kiecker F, Schaefer S, et al. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. J Immunother Cancer. 2020;8(1): e000333. https://doi.org/10.1136/jitc-2019-000333 . - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous